Orexo AB (publ) (ORX.ST)
SEK 20.8
(-5.24%)
SEK 20.8
(-5.24%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 638.8 Million SEK | 2.32% |
| 2022 | 624.3 Million SEK | 10.5% |
| 2021 | 565 Million SEK | -14.86% |
| 2020 | 663.6 Million SEK | -21.45% |
| 2019 | 844.8 Million SEK | 7.88% |
| 2018 | 783.1 Million SEK | 21.66% |
| 2017 | 643.7 Million SEK | -8.8% |
| 2016 | 705.8 Million SEK | 9.71% |
| 2015 | 643.33 Million SEK | 12.8% |
| 2014 | 570.31 Million SEK | 32.83% |
| 2013 | 429.35 Million SEK | 31.59% |
| 2012 | 326.27 Million SEK | 63.45% |
| 2011 | 199.61 Million SEK | -5.17% |
| 2010 | 210.49 Million SEK | -10.84% |
| 2009 | 236.1 Million SEK | 1.18% |
| 2008 | 233.34 Million SEK | 0.0% |
| 2007 | - SEK | -100.0% |
| 2006 | 131.95 Million SEK | 111.63% |
| 2005 | 62.35 Million SEK | -28.1% |
| 2004 | 86.71 Million SEK | 305.97% |
| 2003 | 21.36 Million SEK | 621.38% |
| 2002 | 2.96 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 139.3 Million SEK | -16.08% |
| 2024 Q2 | 154 Million SEK | 10.55% |
| 2024 Q3 | 136.5 Million SEK | -11.36% |
| 2023 Q3 | 156.1 Million SEK | -1.01% |
| 2023 Q4 | 166 Million SEK | 6.34% |
| 2023 FY | 638.8 Million SEK | 2.32% |
| 2023 Q2 | 157.7 Million SEK | -0.69% |
| 2023 Q1 | 158.8 Million SEK | 1.79% |
| 2022 Q1 | 159.4 Million SEK | 10.69% |
| 2022 Q2 | 147.8 Million SEK | -7.28% |
| 2022 Q3 | 161 Million SEK | 8.93% |
| 2022 Q4 | 156 Million SEK | -3.11% |
| 2022 FY | 624.3 Million SEK | 10.5% |
| 2021 FY | 565 Million SEK | -14.86% |
| 2021 Q1 | 132.3 Million SEK | -16.9% |
| 2021 Q2 | 142.8 Million SEK | 7.94% |
| 2021 Q4 | 144 Million SEK | -1.3% |
| 2021 Q3 | 145.9 Million SEK | 2.17% |
| 2020 Q3 | 150.3 Million SEK | -16.08% |
| 2020 Q1 | 175 Million SEK | -26.5% |
| 2020 FY | 663.6 Million SEK | -21.45% |
| 2020 Q2 | 179.1 Million SEK | 2.34% |
| 2020 Q4 | 159.2 Million SEK | 5.92% |
| 2019 Q2 | 201.2 Million SEK | 15.43% |
| 2019 Q3 | 231.2 Million SEK | 14.91% |
| 2019 Q4 | 238.1 Million SEK | 2.98% |
| 2019 FY | 844.8 Million SEK | 7.88% |
| 2019 Q1 | 174.3 Million SEK | -23.25% |
| 2018 Q3 | 216.6 Million SEK | 8.46% |
| 2018 FY | 783.1 Million SEK | 21.66% |
| 2018 Q2 | 199.7 Million SEK | 42.95% |
| 2018 Q4 | 227.1 Million SEK | 4.85% |
| 2018 Q1 | 139.7 Million SEK | -26.9% |
| 2017 Q3 | 166.2 Million SEK | 4.53% |
| 2017 Q2 | 159 Million SEK | 24.8% |
| 2017 Q1 | 127.4 Million SEK | -31.02% |
| 2017 FY | 643.7 Million SEK | -8.8% |
| 2017 Q4 | 191.1 Million SEK | 14.98% |
| 2016 FY | 705.8 Million SEK | 9.71% |
| 2016 Q3 | 181.9 Million SEK | -3.3% |
| 2016 Q2 | 188.1 Million SEK | 24.57% |
| 2016 Q1 | 151 Million SEK | -33.86% |
| 2016 Q4 | 184.7 Million SEK | 1.54% |
| 2015 FY | 643.33 Million SEK | 12.8% |
| 2015 Q1 | 149 Million SEK | -32.43% |
| 2015 Q2 | 126.5 Million SEK | -15.1% |
| 2015 Q3 | 139.5 Million SEK | 10.28% |
| 2015 Q4 | 228.3 Million SEK | 63.66% |
| 2014 Q2 | 117.3 Million SEK | 15.11% |
| 2014 Q4 | 220.51 Million SEK | 68.72% |
| 2014 FY | 570.31 Million SEK | 32.83% |
| 2014 Q3 | 130.7 Million SEK | 11.42% |
| 2014 Q1 | 101.9 Million SEK | 2.46% |
| 2013 Q1 | 139.8 Million SEK | 67.27% |
| 2013 Q2 | 69 Million SEK | -50.64% |
| 2013 Q4 | 99.45 Million SEK | -17.87% |
| 2013 Q3 | 121.1 Million SEK | 75.51% |
| 2013 FY | 429.35 Million SEK | 31.59% |
| 2012 FY | 326.27 Million SEK | 63.45% |
| 2012 Q4 | 83.57 Million SEK | 9.83% |
| 2012 Q2 | 82.9 Million SEK | -0.84% |
| 2012 Q3 | 76.1 Million SEK | -8.2% |
| 2012 Q1 | 83.6 Million SEK | 47.38% |
| 2011 FY | 199.61 Million SEK | -5.17% |
| 2011 Q4 | 56.72 Million SEK | 22.72% |
| 2011 Q3 | 46.22 Million SEK | -16.26% |
| 2011 Q2 | 55.2 Million SEK | 33.14% |
| 2011 Q1 | 41.46 Million SEK | -62.01% |
| 2010 Q3 | 35.85 Million SEK | 23.33% |
| 2010 Q1 | 36.43 Million SEK | 30.8% |
| 2010 FY | 210.49 Million SEK | -10.84% |
| 2010 Q2 | 29.07 Million SEK | -20.22% |
| 2010 Q4 | 109.13 Million SEK | 204.39% |
| 2009 FY | 236.1 Million SEK | 1.18% |
| 2009 Q1 | 114.94 Million SEK | 24.76% |
| 2009 Q2 | 29.62 Million SEK | -74.23% |
| 2009 Q3 | 63.67 Million SEK | 114.95% |
| 2009 Q4 | 27.85 Million SEK | -56.25% |
| 2008 Q3 | 60.97 Million SEK | 0.0% |
| 2008 Q4 | 92.13 Million SEK | 51.12% |
| 2008 FY | 233.34 Million SEK | 0.0% |
| 2007 FY | - SEK | -100.0% |
| 2006 FY | 131.95 Million SEK | 111.63% |
| 2005 FY | 62.35 Million SEK | -28.1% |
| 2004 FY | 86.71 Million SEK | 305.97% |
| 2003 FY | 21.36 Million SEK | 621.38% |
| 2002 FY | 2.96 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 1.29 Billion SEK | 50.729% |
| Enzymatica AB (publ) | 50.9 Million SEK | -1154.911% |
| Enorama Pharma AB (publ) | 1.35 Million SEK | -46939.764% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | - SEK | -Infinity% |
| Nanexa AB (publ) | 29.32 Million SEK | -2078.198% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | -1634.503% |
| ODI Pharma AB | 22.44 Million SEK | -2745.799% |
| Probi AB (publ) | 627.68 Million SEK | -1.77% |
| Swedencare AB (publ) | 2.32 Billion SEK | 72.52% |
| Swedish Orphan Biovitrum AB (publ) | 22.12 Billion SEK | 97.113% |
| Toleranzia AB | 50.92 Million SEK | -1154.517% |
| Vivesto AB | 1.01 Million SEK | -62835.961% |